Mikala Egeblad
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Recognitions
Mikala Egeblad has a total of 617 co-authors. Here are the top co-authors by number of shared publications:
- Jose M. Adrover
Cancer Macroenvironment Lab, The Francis Crick Institute, London, UK
53 shared publications - Alexandra Wuest
David H. Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA, USA
48 shared publications - Caroline Broderick
Department of Cancer Biology and Genetics, Memorial Sloan Kettering Cancer Center, New York, New York
48 shared publications - Changyu Zhu
Department of Medicine, Columbia University, New York, NY 10032, USA
48 shared publications - Direna Alonso-Curbelo
Cancer Biology and Genetics Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA
48 shared publications - Georgia Schmitt
Calico Life Sciences, South San Francisco, California
48 shared publications
Latest Publications
- 20 May 2026
- Published by Elsevier in Trends in Immunology
- Vol. 47 (6) , 453-455
Hijacked on arrival: glucocorticoids enable disseminated tumor cell immune evasion
- 20 May 2026
- Published by Elsevier in Trends in Immunology
- Vol. 47 (6) , 453-455
Hijacked on arrival: glucocorticoids enable disseminated tumor cell immune evasion
- Open Access
- 11 December 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table S1 from Senescence Rewires Microenvironment Sensing to Facilitate Antitumor Immunity
Differential expression analyses of CD8 T and macrophages populations of proliferating (p53 off) vs. senescent (p53 on) tumors by scRNA-seq.
- 11 December 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S1 from Senescence Rewires Microenvironment Sensing to Facilitate Antitumor Immunity
Differential expression analyses of CD8 T and macrophages populations of proliferating (p53 off) vs. senescent (p53 on) tumors by scRNA-seq.
- Open Access
- 11 December 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table S3 from Senescence Rewires Microenvironment Sensing to Facilitate Antitumor Immunity
Low (50 pg/ml) and high (1 ng/ml) dose of IFN-γ treatment in proliferating and senescent NSP cells.
- 11 December 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S3 from Senescence Rewires Microenvironment Sensing to Facilitate Antitumor Immunity
Low (50 pg/ml) and high (1 ng/ml) dose of IFN-γ treatment in proliferating and senescent NSP cells.
- Open Access
- 11 December 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Video S1 from Senescence Rewires Microenvironment Sensing to Facilitate Antitumor Immunity
Supplementary Video S1 from Senescence Rewires Microenvironment Sensing to Facilitate Antitumor Immunity
- 11 December 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Video S1 from Senescence Rewires Microenvironment Sensing to Facilitate Antitumor Immunity
Supplementary Video S1 from Senescence Rewires Microenvironment Sensing to Facilitate Antitumor Immunity
- Open Access
- 11 December 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Video S2 from Senescence Rewires Microenvironment Sensing to Facilitate Antitumor Immunity
Supplementary Video S2 from Senescence Rewires Microenvironment Sensing to Facilitate Antitumor Immunity
- 11 December 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Video S2 from Senescence Rewires Microenvironment Sensing to Facilitate Antitumor Immunity
Supplementary Video S2 from Senescence Rewires Microenvironment Sensing to Facilitate Antitumor Immunity
- Open Access
- 11 December 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S1-S16 from Senescence Rewires Microenvironment Sensing to Facilitate Antitumor Immunity
Supplementary figures complement main figures to show that senescent cells have a rewired environmental signal sensing phenotype, exemplified by an enhanced IFN-g signaling, to facilitate anti-tumor immunity.
- 11 December 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S1-S16 from Senescence Rewires Microenvironment Sensing to Facilitate Antitumor Immunity
Supplementary figures complement main figures to show that senescent cells have a rewired environmental signal sensing phenotype, exemplified by an enhanced IFN-g signaling, to facilitate anti-tumor immunity.
- Open Access
- 11 December 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table S2 from Senescence Rewires Microenvironment Sensing to Facilitate Antitumor Immunity
RNA-Seq data of proliferating (PRO) or senescent (SEN) NSP liver tumor cells, for both p53-restoration and drug-induced (trametinib+palbociclib) settings. PRO and SEN cells were also treated with the BET inhibitor JQ-1 (500 n, 48 h), to expose BRD4-mediated transcriptional output in each cellular state.
- 11 December 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S2 from Senescence Rewires Microenvironment Sensing to Facilitate Antitumor Immunity
RNA-Seq data of proliferating (PRO) or senescent (SEN) NSP liver tumor cells, for both p53-restoration and drug-induced (trametinib+palbociclib) settings. PRO and SEN cells were also treated with the BET inhibitor JQ-1 (500 n, 48 h), to expose BRD4-mediated transcriptional output in each cellular state.
- Open Access
- 11 December 2025
- Published by American Association for Cancer Research (AACR)
Data from Senescence Rewires Microenvironment Sensing to Facilitate Antitumor Immunity
Cellular senescence involves a stable cell-cycle arrest coupled to a secretory program that, in some instances, stimulates the immune clearance of senescent cells. Using an immune-competent liver cancer model in which senescence triggers CD8 T cell–mediated tumor rejection, we show that senescence also remodels the cell-surface proteome to alter how tumor cells sense environmental factors, as exemplified by type II interferon (IFNγ). Compared with proliferating cells, senescent cells upregulate the IFNγ receptor, become hypersensitized to microenvironmental IFNγ, and more robustly induce the antigen-presenting machinery—effects also recapitulated in human tumor cells undergoing therapy-induced senescence. Disruption of IFNγ sensing in senescent cells blunts their immune-mediated clearance without disabling the senescence state or its characteristic secretory program. Our results demonstrate that senescent cells have an enhanced ability to both send and receive environmental signals and imply that each process is required for their effective immune surveillance.Significance:Our work uncovers an interplay between tissue remodeling and tissue-sensing programs that can be engaged by senescence in advanced cancers to render tumor cells more visible to the adaptive immune system. This new facet of senescence establishes reciprocal heterotypic signaling interactions that can be induced therapeutically to enhance antitumor immunity.See the interview with Direna Alonso-Curbelo, PhD, recipient of the inaugural Cancer Discovery Early Career Award: https://vimeo.com/992987447See related article by Marin et al., p. 410.This article is highlighted in the In This Issue feature, p. 247
- 11 December 2025
- Published by American Association for Cancer Research (AACR)
Open AccessData from Senescence Rewires Microenvironment Sensing to Facilitate Antitumor Immunity
Cellular senescence involves a stable cell-cycle arrest coupled to a secretory program that, in some instances, stimulates the immune clearance of senescent cells. Using an immune-competent liver cancer model in which senescence triggers CD8 T cell–mediated tumor rejection, we show that senescence also remodels the cell-surface proteome to alter how tumor cells sense environmental factors, as exemplified by type II interferon (IFNγ). Compared with proliferating cells, senescent cells upregulate the IFNγ receptor, become hypersensitized to microenvironmental IFNγ, and more robustly induce the antigen-presenting machinery—effects also recapitulated in human tumor cells undergoing therapy-induced senescence. Disruption of IFNγ sensing in senescent cells blunts their immune-mediated clearance without disabling the senescence state or its characteristic secretory program. Our results demonstrate that senescent cells have an enhanced ability to both send and receive environmental signals and imply that each process is required for their effective immune surveillance.Significance:Our work uncovers an interplay between tissue remodeling and tissue-sensing programs that can be engaged by senescence in advanced cancers to render tumor cells more visible to the adaptive immune system. This new facet of senescence establishes reciprocal heterotypic signaling interactions that can be induced therapeutically to enhance antitumor immunity.See the interview with Direna Alonso-Curbelo, PhD, recipient of the inaugural Cancer Discovery Early Career Award: https://vimeo.com/992987447See related article by Marin et al., p. 410.This article is highlighted in the In This Issue feature, p. 247
- Open Access
- 15 November 2025
- Published by Springer Nature in Nature Communications
- Vol. 16 (1) , 9996
KLF5 enables dichotomous lineage programs in pancreatic cancer via the AAA+ ATPase coactivators RUVBL1 and RUVBL2
Lineage plasticity is a hallmark of pancreatic ductal adenocarcinoma (PDAC) and contributes to tumor heterogeneity and therapeutic resistance. Here, we identify KLF5 as a dynamic master regulator of epithelial lineage identity in PDAC, with dichotomous roles in promoting either classical or basal-like transcriptional programs. Through unbiased proteomic and genetic screens, we uncover the AAA+ ATPases RUVBL1 and RUVBL2 as essential coactivators of KLF5 across both lineage states. We demonstrate that ATP hydrolysis by RUVBL1/2 is required for the stable interaction with an intrinsically disordered region of KLF5, enabling its recruitment to lineage-specific enhancers and driving transcriptional regulation of identity-defining genes. Notably, small-molecule inhibitors of RUVBL1/2 ATPase activity, which have anti-PDAC activity in vivo, suppress KLF5-dependent transcription. These findings define a previously unrecognized mechanism of ATP hydrolysis-dependent transcriptional coactivation and highlight a potential therapeutic strategy for modulating aberrant lineage programs in cancer.
- 15 November 2025
- Published by Springer Nature in Nature Communications
- Vol. 16 (1) , 9996
Open AccessKLF5 enables dichotomous lineage programs in pancreatic cancer via the AAA+ ATPase coactivators RUVBL1 and RUVBL2
Lineage plasticity is a hallmark of pancreatic ductal adenocarcinoma (PDAC) and contributes to tumor heterogeneity and therapeutic resistance. Here, we identify KLF5 as a dynamic master regulator of epithelial lineage identity in PDAC, with dichotomous roles in promoting either classical or basal-like transcriptional programs. Through unbiased proteomic and genetic screens, we uncover the AAA+ ATPases RUVBL1 and RUVBL2 as essential coactivators of KLF5 across both lineage states. We demonstrate that ATP hydrolysis by RUVBL1/2 is required for the stable interaction with an intrinsically disordered region of KLF5, enabling its recruitment to lineage-specific enhancers and driving transcriptional regulation of identity-defining genes. Notably, small-molecule inhibitors of RUVBL1/2 ATPase activity, which have anti-PDAC activity in vivo, suppress KLF5-dependent transcription. These findings define a previously unrecognized mechanism of ATP hydrolysis-dependent transcriptional coactivation and highlight a potential therapeutic strategy for modulating aberrant lineage programs in cancer.